Immune checkpoint inhibitors are a new class of oncologic drugs that act via the inhibition of
checkpoints, thereby unlocking the immune system to attack cancer cells. Their emergence …

The introduction of immune checkpoint inhibitors as a treatment modality in advanced
malignancies has revolutionized the field of oncology therapeutics. Immunotherapy …

Immune checkpoint inhibitors (ICIs) have revolutionized treatment strategies in the field of
oncology. Their favourable outcomes in terms of efficacy and side-effect profile can be …

The introduction of immune checkpoint inhibitors (ICIs) opened a new era in oncologic
therapy. The favourable profile of ICIs in terms of efficacy and safety can be overshadowed …

Immune checkpoints assist with self-tolerance and minimize collateral tissue damage when
immune responses are activated. Although immune checkpoint inhibitors (CPIs) are …

The development of immunotherapy has led to a paradigm shift in the treatment of both solid
and hematologic malignancies. As immunomodulatory therapies are employed with …

Background Cutaneous immune‐related adverse events (irAEs) represent the most frequent
toxicities induced by immune checkpoint inhibitors (ICIs). Objectives To investigate clinical …

Uncoupling toxicity from therapeutic effect lies at the foundation of the current state of the
field of cutaneous immune‐related adverse events to immune checkpoint inhibitor therapy …

Immune checkpoint inhibitors have proven to be efficacious for a broad spectrum of solid
organ malignancies. These monoclonal antibodies lead to cytotoxic T-cell activation and …

Immune checkpoint inhibitors (ICIs) have emerged as novel options that are effective in
treating various cancers. They are monoclonal antibodies that target cytotoxic T-lymphocyte …